Engineered immune cells take on Hard-to-Treat cancers
Disease control
Recruiting now
This early study is testing a new treatment called Anti-HER2 CAR-T cells in 30 adults with advanced solid tumors that have the HER2 protein and have not responded to standard treatments. Participants first receive chemotherapy, then an infusion of the engineered immune cells. The…
Phase: NA • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC